Core Viewpoint - AnuoYuda Gene Technology (Beijing) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CCB International and Guotai Junan International as joint sponsors. The company previously submitted its listing application on March 25 [1]. Company Overview - AnuoYuda specializes in molecular diagnostics-based IVD medical devices and multi-omics life science research services, focusing on NGS-based prenatal testing IVD products. Its clinical sequencing solutions include self-produced IVD testing kits, gene sequencers, and bioinformatics analysis software, along with technical support and laboratory design services [3][4]. - The company's clients primarily consist of hospitals certified for prenatal diagnosis and independent medical laboratories (ICLs), which purchase IVD products and pay fees based on the number and type of products purchased [3]. Market Position - AnuoYuda's NIPT testing kit, aimed at detecting the three most common chromosomal disorders (trisomy 21, 18, and 13), received Class III medical device certification in 2017, establishing its market position in prenatal testing. According to ZhiShi Consulting, AnuoYuda ranks second in China's NIPT market by sample testing volume in 2024, with market shares of 11.6%, 12.1%, and 15.5% for 2022, 2023, and 2024, respectively. By revenue, the company ranks third in the NIPT market with a market share of 14.6% [3]. Product Offerings - The company provides two types of life science sequencing solutions: clinical sequencing solutions and research sequencing solutions. In the clinical sequencing solutions line, AnuoYuda procures reagents and equipment components from upstream suppliers and sells IVD testing kits, proprietary gene sequencers, and bioinformatics software to hospitals and independent medical laboratories [4]. - In the research sequencing solutions line, the company sources gene sequencers, testing kits, and other equipment from upstream suppliers to offer six types of research sequencing solutions to academic institutions, research organizations, and corporate clients, primarily for multi-omics research in agriculture, forestry, animal husbandry, and fisheries [4]. Production Capacity - As of September 23, 2025, AnuoYuda operates three production facilities in China, primarily producing testing kits and sequencers. During the reporting period, the combined annual production capacity of the facilities is 40 NextSeq550AR sequencers and 48,000 testing kits [4]. Financial Performance - The company's revenue from continuing operations for the six months ended June 30 for the years 2022, 2023, 2024, and 2025 was approximately RMB 435.1 million, RMB 475.0 million, RMB 518.1 million, and RMB 269.3 million, respectively. The annual losses for the same periods were approximately RMB 67 million, RMB 240 million, RMB 126 million, and RMB 29 million [6][7].

Core Viewpoint - Anuo Youda has submitted its listing application to the Hong Kong Stock Exchange, marking its journey towards going public, backed by influential figure Xia Zuoquan, co-founder of BYD and angel investor in UBTECH [1] Company Overview - Anuo Youda, founded in 2012 by Xia Zuoquan, specializes in IVD medical devices and multi-omics life science research services, becoming a pioneer in NGS-based prenatal testing IVD products [1][3] - The company has developed a comprehensive IVD product portfolio, including approved testing kits, sequencers, and compatible bioinformatics analysis software [3] Market Position - According to data from Zhaoshang Consulting, Anuo Youda ranks third in the Chinese NIPT market by sample testing volume, with a market share of 12.1% [2][3] - The company has significantly increased its sales of IVD products to 86 certified hospitals across 26 provinces, reflecting a growing demand for its offerings [3] Financial Performance - Anuo Youda's revenue projections for 2022 to 2024 are 435 million, 475 million, and 518 million yuan, indicating an upward trend in market demand [3] - Despite rapid business growth, the company is currently operating at a loss, with projected losses of 66.81 million, 240 million, and 126 million yuan for the same period [4] Shareholder Structure - The company boasts a strong shareholder structure, including notable investors such as China Life, Northern Light Venture Capital, Guotai Junan, Ping An Group, and Sequoia Capital, providing financial support and strategic guidance [4] - Xia Zuoquan controls 54.25% of the voting rights through direct and indirect holdings, although daily management is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industry [4][5] Leadership - Xia Zuoquan is recognized for his visionary leadership and business acumen, which are key to Anuo Youda's success, alongside CEO Li Zhimin's extensive industry insights [5]

Core Viewpoint - Anuo Youda, an IVD medical device company, has officially begun its listing process on the Hong Kong Stock Exchange, backed by founder Xia Zuoquan, who is also a co-founder of BYD and a significant investor in UBTECH [1][3]. Company Overview - Anuo Youda was established in April 2012 and transitioned to a joint-stock company in March 2025, focusing on molecular diagnostics and IVD medical devices, particularly in non-invasive prenatal testing (NIPT) [3][8]. - The company has developed a comprehensive IVD product portfolio, including NIPT kits and sequencing instruments, and is recognized as a pioneer in the NGS-based prenatal testing market [4][5]. Market Position - Anuo Youda ranks third in the Chinese NIPT market, with market shares increasing from 9.6% in 2021 to 12.1% in 2023, indicating a growing demand for its IVD products [4][6]. - The company has sold IVD products to 86 hospitals with prenatal diagnostic certification across 26 provinces, a significant increase from 61 hospitals in December 2023 [6]. Financial Performance - Anuo Youda reported revenues of RMB 4.35 billion, RMB 4.75 billion, and RMB 5.18 billion for the years 2022, 2023, and 2024, respectively, but continues to operate at a loss, with losses of RMB 668.1 million, RMB 2.4 billion, and RMB 1.26 billion for the same years [8][6]. - The revenue from clinical sequencing solutions has shown an upward trend, with income from 2022 to 2024 increasing from RMB 2.51 billion to RMB 3.29 billion, driven by higher sales of NIPT and CNV-seq kits [6]. Shareholder Structure - Xia Zuoquan controls 54.25% of the voting rights in Anuo Youda, with a strong backing from notable investors such as China Life, Northern Light Venture Capital, and Ping An Group [9][11][15]. - The company has a robust shareholder base that provides financial support and strategic guidance, enhancing its growth prospects [11]. Management Team - The management team is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industries, bringing valuable insights and relationships to the company [16].

Core Viewpoint - Anuo Youda, an IVD medical device company, has officially begun its journey to list on the Hong Kong Stock Exchange, backed by founder Xia Zuoquan, who is also a co-founder of BYD and an angel investor in UBTECH [1][2]. Company Overview - Anuo Youda was established in April 2012 and focuses on molecular diagnostics and IVD medical devices, particularly in non-invasive prenatal testing (NIPT) [5][6]. - The company has developed a comprehensive IVD product portfolio, including NIPT kits that received regulatory approval in 2017, positioning it as a leader in the prenatal testing market in China [6][9]. Market Position - As of 2023, Anuo Youda ranks third in the Chinese NIPT market, with market shares increasing from 9.6% in 2021 to 12.1% in 2023 [6][9]. - The company has expanded its customer base significantly, selling IVD products to 86 hospitals certified for prenatal diagnosis across 26 provinces, up from 61 hospitals in 2023 [9]. Financial Performance - Anuo Youda reported revenues of RMB 4.35 billion, RMB 4.75 billion, and RMB 5.18 billion for the years 2022, 2023, and 2024, respectively, while still operating at a loss [9][10]. - The losses for the same years were RMB 668.1 million, RMB 240.2 million, and RMB 125.8 million, indicating a trend of increasing revenue but persistent financial challenges [9][10]. Shareholder Structure - Xia Zuoquan controls 54.25% of the voting rights in Anuo Youda, with a strong backing from notable investors such as China Life, Northern Light Venture Capital, and others [11][14]. - The company has a robust shareholder base that provides financial support and strategic guidance, enhancing its growth prospects [14]. Management Team - The management team is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industries, bringing valuable insights and relationships to the company [19].